Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Uterine Corpus Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
31 drugs · 147 active trials
4 drugs · 55 active trials
Data updated 13 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Sapanisertib | Phase 2 | Phase 2 | 3 | 1 | 0 | 4 | 0 | — | — | May 20, 2014 |
| Talazoparib | Phase 2 | Phase 2 | 3 | 2 | 0 | 4 | 0 | — | — | Oct 1, 2014 |
| Elacestrant | Phase 2 | Phase 2 | 3 | 2 | 0 | 3 | 0 | — | — | Oct 1, 2025 |
| Ipilimumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 7 | 0 | — | — | Oct 1, 2012 |
| Oxaliplatin | Phase 2 | Phase 2 | 2 | 2 | 0 | 5 | 0 | — | — | 1999-11 |
| Leucovorin | Phase 2 | Phase 2 | 2 | 2 | 0 | 4 | 0 | — | — | Nov 21, 2017 |
| Mirvetuximab Soravtansine | Phase 2 | Phase 2 | 2 | 1 | 0 | 4 | 0 | — | — | Jul 12, 2018 |
| Avelumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Nov 14, 2016 |
| Cyclophosphamide | Phase 2 | Phase 2 | 2 | 2 | 0 | 3 | 0 | — | — | Jul 1, 2017 |
| Ribociclib | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Aug 18, 2017 |
| Selumetinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | 2009-09 |
| Alpelisib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Dec 10, 2019 |
| Binimetinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Cemiplimab | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | May 21, 2018 |
| Datopotamab Deruxtecan | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Nov 12, 2020 |
| Imlunestrant | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Dec 10, 2019 |
| Inavolisib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Oct 20, 2021 |
| Pertuzumab | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Temsirolimus | Phase 2 | Phase 2 | 1 | 0 | 0 | 13 | 0 | — | — | 2004-05 |
| Pemetrexed | Phase 2 | Phase 2 | 1 | 1 | 0 | 6 | 0 | — | — | 2006-03 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | Aug 17, 2015 |
| Sunitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2006-10 |
| Dasatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | Sep 20, 2011 |
| Adavosertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Anastrozole | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2016-04 |
| Capecitabine | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Apr 29, 2002 |
| Cediranib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2010-02 |
| Cetuximab | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2005-01 |
| Dordaviprone | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Jun 8, 2017 |
| Trabectedin | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2011-02 |
| Tremelimumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2017-01 |
| Veliparib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2011-02 |
| Axitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Nov 14, 2016 |
| Camrelizumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Jan 23, 2019 |
| Enzalutamide | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Aug 24, 2016 |
| Samotolisib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | 2015-09 |
| Temozolomide | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 1998-09 |
| Toripalimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jul 25, 2023 |
| Trametinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Sep 30, 2013 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2010-06 |
| Vistusertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Nov 11, 2014 |
| Zanidatamab | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Aug 12, 2020 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Belzutifan | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Dec 20, 2024 |
| Camizestrant | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 12, 2020 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Dabrafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Enfortumab Vedotin | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jul 10, 2026 |
| Erdafitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.